Low
₹1,530.40
High
₹1,610.00
| Previous Close | ₹1,562.70 |
|---|---|
| Day's Range | ₹1,530.40 - ₹1,610.00 |
| Open | ₹1,580.00 |
| 52 Week Range | ₹799.42 - ₹2,178.46 |
| Volume | 1,07,066 |
| Market Cap | ₹0.00 |
| Previous Close | ₹1,564.35 |
|---|---|
| Day's Range | ₹1,529.20 - ₹1,609.30 |
| Open | ₹1,586.00 |
| 52 Week Range | ₹631.32 - ₹2,178.48 |
| Volume | 6,647 |
| Market Cap | ₹0.00 |
| Trade Value ( ₹ in Lacs) | 1,673.12 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.62 |
| P/E Ratio | 25.71 |
| Book Value(₹) | 5.96 |
| PAT Margin (%) | 24.72 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 16.34 |
| Trade Value ( ₹ in Lacs) | 103.98 |
|---|---|
| Market Cap (₹ in Mn) | 0.00 |
| Dividend Yield(%) | 0.00 |
| Price/Earning (TTM) | 0.00 |
| TTM EPS (₹) | -1.62 |
| P/E Ratio | 25.71 |
| Book Value(₹) | 5.96 |
| PAT Margin (%) | 24.72 |
| Face Value (₹) | 5.00 |
| ROCE(%) | 16.34 |
| Particulars | QTR FY (₹ in Millions) | Annual FY (₹ in Millions) |
|---|---|---|
| Net sales | 903.3 | 3562.7 |
| Expenses | N/A | N/A |
| PBT | 326.5 | 1304.2 |
| Operating profit | 0.0 | 0.0 |
| Net profit | 242.2 | 1009.0 |
| Founded | 1947 |
|---|---|
| Managing Director | Vikas Gupta |
| NSE Symbol | EVONILE |
| Stocks Name | Market Cap (Cr)(₹) | Market Price (₹) | 52 Week Low-High (₹) |
|---|---|---|---|
| Adani Enterprises Ltd. | 3,66,317.34 | 2,708.30 | 1,753.00 - 1,753.00 |
| Aditya Infotech Ltd. | 51,826.52 | 4,211.00 | 0.00 - 0.00 |
| Aegis Logistics Ltd. | 43,050.15 | 1,225.00 | 576.10 - 576.10 |
| Premier Energies Ltd. | 40,174.71 | 886.50 | 660.00 - 660.00 |
| Redington Ltd. | 25,681.29 | 344.50 | 191.31 - 191.31 |
| Honasa Consumer Ltd. | 15,778.91 | 485.80 | 248.40 - 248.40 |
| SG Mart Ltd. | 11,373.17 | 908.45 | 313.10 - 313.10 |
| Lloyds Enterprises Ltd. | 9,816.62 | 66.98 | 40.69 - 40.69 |
| Entero Healthcare Solutions Ltd. | 9,213.82 | 2,004.95 | 944.00 - 944.00 |
| Cello World Ltd. | 8,238.91 | 366.30 | 314.00 - 314.00 |
No Records Found
Pursuant to Regulation 10(1A) and other applicable provisions of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated December 31, 2024, BSE Circular No. 20250102-4 and NSE Circular No. NSE/CML/2025/02 dated January 2, 2025, Evonile Pharma has submitted the revised Integrated Filing (Financial) for the quarter and half year ended September 30, 2026, comprising the Unaudited Financial Statements together with the Limited Review Report thereon (Annexures I and II) and other disclosures forming part of the said filing. This revised filing is being submitted solely to rectify an inadvertent omission in the heading of the table appearing under ‘Disclosure of Outstanding Default on Loans and Debt Securities’ on page 2 of the disclosure submitted earlier on November 03, 2026, at 7:23 p.m. While the figures disclosed in the table were correctly stated, the expression ‘(INR in crores)’ was inadvertently omitted from the column heading. Accordingly, it has clarified that the amount disclosed against ‘A. Total amount outstanding as on date’ under ‘Loans/Revolving Facilities like Cash Credit from Banks/Financial Institutions’ should be read as ₹800 crores as on September 30, 2026. Further, the amount disclosed against ‘Total financial indebtedness of the listed entity including short-term and long-term debt’ should also be read as ₹800 crores. The company has confirmed that all other disclosures and particulars contained in the earlier submission remain unchanged. There is no change whatsoever in the Unaudited Financial Results, Limited Review Report, Related Party Transactions disclosure, or any other information forming part of the Integrated Filing (Financial). This revised filing is being made solely to correct the aforesaid omission in the table heading.
The above information is a part of company’s filings submitted to BSE.
In continuation to its earlier intimation dated November 2, 2026, regarding the Board Meeting scheduled on Thursday, November 12, 2026, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2026. Adhata Global has informed that due to unavoidable circumstances, the said Board Meeting has been rescheduled and will now be held on Saturday, November 14, 2026, to consider and approve the unaudited financial results of the Company for the quarter and half year ended September 30, 2026. Further, in pursuance to SEBI (Prohibition of Insider Trading) Regulations, 2015, the ‘Trading Window’ for dealing in the securities of Company, has been closed from Thursday, 01st October, 2026, till 48 hours after the declaration of Financial Results.
The above information is a part of company’s filings submitted to BSE.
Natural Biocon (India) has informed that the meeting of the Board of Directors of the Company is scheduled on 14/11/2026, inter alia, to consider and approve The unaudited financial results along with the limited review report of the Company for the quarter and half-year ended September 30th, 2026 and other business items, if any.
The above information is a part of company’s filings submitted to BSE.
No Records Found
The current share price of Evonile Pharma Ltd. is ₹1,562.70 as of 2026-11-11.
The market capitalisation of Evonile Pharma Ltd. is ₹4,596.19 as of 2026-11-09.
The 1-year return of Evonile Pharma Ltd. is % as of .
The P/E ratio of Evonile Pharma Ltd. is 25.71 as of 2026-11-11.
The 52-week high and low of Evonile Pharma Ltd. are ₹2,178.46 and ₹799.42, respectively, as of 2026-11-11.
All content and research information displayed on the Site, are obtained from our partner Accord Fintech Private Limited. an authorized data feed vendor of BSE/NSE/MCX/NCDEX exchange. The data is provided on ‘As-Is’ basis and is not a live data feed but a feed with 15 minutes delay or more. Bajaj Markets does not warrant accuracy, completeness, timely availability of the information and data available on the Site. Past performance, when presented, is purely for reference purposes and is not a guarantee of similar future results.
The Services offered on the Site does not constitute investment advice in any manner whatsoever. You shall be solely responsible for any investment decisions made by placing reliance on the information provided on the Site.
Bajaj Markets partners with financial services entities for sourcing leads for services such as DEMAT accounts etc. In case you wish to avail the services, you shall be redirected to partners platform and shall be bound by the terms and conditions, privacy policy governing the said platform.